Exploring selective inhibition of the first bromodomain of the human bromodomain and extra-terminal domain (BET) proteins
B Raux, Y Voitovich, C Derviaux, A Lugari… - Journal of medicinal …, 2016 - ACS Publications
A midthroughput screening follow-up program targeting the first bromodomain of the human
BRD4 protein, BRD4(BD1), identified an acetylated-mimic xanthine derivative inhibitor. This …
BRD4 protein, BRD4(BD1), identified an acetylated-mimic xanthine derivative inhibitor. This …
[HTML][HTML] From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia
…, P Brémond, E Rebuffet, P Roche, C Derviaux… - Nature …, 2023 - nature.com
Cancer cells utilize the main de novo pathway and the alternative salvage pathway for
deoxyribonucleotide biosynthesis to achieve adequate nucleotide pools. Deoxycytidine kinase is …
deoxyribonucleotide biosynthesis to achieve adequate nucleotide pools. Deoxycytidine kinase is …
Integrated strategy for lead optimization based on fragment growing: the diversity-oriented-target-focused-synthesis approach
…, C Muller, AY Fedorov, C Derviaux… - Journal of medicinal …, 2018 - ACS Publications
Over the past few decades, hit identification has been greatly facilitated by advances in high-throughput
and fragment-based screenings. One major hurdle remaining in drug discovery …
and fragment-based screenings. One major hurdle remaining in drug discovery …
Fr-PPIChem: An academic compound library dedicated to protein–protein interactions
…, L Hoffer, D Lagorce, S Bourg, C Derviaux… - ACS chemical …, 2020 - ACS Publications
Protein–protein interactions (PPIs) mediate nearly every cellular process and represent
attractive targets for modulating disease states but are challenging to target with small molecules…
attractive targets for modulating disease states but are challenging to target with small molecules…
Protein–protein interaction inhibition (2P2I)-oriented chemical library accelerates hit discovery
Protein–protein interactions (PPIs) represent an enormous source of opportunity for
therapeutic intervention. We and others have recently pinpointed key rules that will help in …
therapeutic intervention. We and others have recently pinpointed key rules that will help in …
[HTML][HTML] Genetic, structural, and chemical insights into the dual function of GRASP55 in germ cell Golgi remodeling and JAM-C polarized localization during …
…, A Lugari, V Hamon, F Bardin, C Derviaux… - PLoS …, 2017 - journals.plos.org
Spermatogenesis is a dynamic process that is regulated by adhesive interactions between
germ and Sertoli cells. Germ cells express the Junctional Adhesion Molecule-C (JAM-C, …
germ and Sertoli cells. Germ cells express the Junctional Adhesion Molecule-C (JAM-C, …
Design and validation of a homogeneous time-resolved fluorescence-based leptin receptor binding assay
V Vauthier, C Derviaux, N Douayry, T Roux… - Analytical …, 2013 - Elsevier
The pleiotropic cytokine hormone leptin, by activating its receptor OB-R, plays a major role
in many biological processes, including energy homeostasis, immune function, and cell …
in many biological processes, including energy homeostasis, immune function, and cell …
Fragment-based drug design targeting syntenin PDZ2 domain involved in exosomal release and tumour spread
…, F Benmansour, M Feracci, C Derviaux… - European Journal of …, 2021 - Elsevier
Syntenin stimulates exosome production and its expression is upregulated in many cancers
and implicated in the spread of metastatic tumor. These effects are supported by syntenin …
and implicated in the spread of metastatic tumor. These effects are supported by syntenin …
Gain of affinity for VEGF165 binding within the VEGFR2/NRP1 cellular complex detected by an HTRF-based binding assay
…, C Roujeau, ZB Choucair, A Oishi, C Derviaux… - Biochemical …, 2018 - Elsevier
Neuroplin 1 (NRP1), a transmembrane protein interacting with Vascular Endothelial Growth
Factor VEGF-A 165 (called here VEGF165) and the tyrosine kinase Receptor 2 (VEGFR2) …
Factor VEGF-A 165 (called here VEGF165) and the tyrosine kinase Receptor 2 (VEGFR2) …
CRCM5484: A BET-BDII selective compound with differential anti-leukemic drug modulation
K Carrasco, C Montersino, C Derviaux… - Journal of Medicinal …, 2022 - ACS Publications
Differentially screening the Fr-PPIChem chemical library on the bromodomain and extra-terminal
(BET) BRD4-BDII versus -BDI bromodomains led to the discovery of a BDII-selective …
(BET) BRD4-BDII versus -BDI bromodomains led to the discovery of a BDII-selective …